Association of Age with Metabolic Biomarkers and Insulin Resistance in Patients with Type 2 Diabetes in Basrah, Iraq

• Mohammed Adil Abdulhassan

  1Al-Zahra ,a Medical College - University of Basrah, Basrah

• Shurok Namah khudair

  Iraqi Ministry of Health, Basrah Health Directorate, Basrah

• Khairallah A.S Mohammed

  College of Health and Medical Techniques /Basra, Southern Technical University, Basra

• Abdulaziz Qadori Abdulsada

  Iraqi Ministry of Health, Basrah Health Directorate, Basrah

General Background: Type 2 diabetes mellitus (T2DM) is an age-related metabolic disorder characterized by progressive metabolic deterioration. Specific Background: Orexin-A and cathepsin-D have been implicated in hypothalamic regulation and cellular quality control, yet their age-related alterations in T2DM remain insufficiently characterized. Knowledge Gap: The interplay between aging, hypothalamic dysfunction, and cellular stress markers in relation to insulin resistance has not been comprehensively explored. Aims: This study investigated age-associated changes in orexin-A and cathepsin-D and their correlations with insulin resistance in T2DM patients. Results: A cross-sectional analysis of 110 T2DM patients and 70 controls revealed a significant age-related decline in orexin-A levels (69% reduction, p=0.001) and an increase in cathepsin-D levels (p=0.005). Orexin-A showed a negative correlation with insulin resistance (r = -0.26, p = 0.005), whereas age and cathepsin-D were positively correlated with HOMA-IR. Traditional metabolic markers, including HbA1c, triglycerides, and LDL, worsened with age. Regression analysis identified age, BMI, and cathepsin-D as positive predictors, while orexin-A was a negative predictor of insulin resistance. Novelty: This study identifies a previously unreported relationship between declining orexin-A and increasing cathepsin-D levels as age progresses in T2DM. Implications: These findings highlight the relevance of age-specific metabolic pathways and suggest the need for tailored therapeutic approaches in older diabetic populations.

Highlights:
• Progressive reduction of orexin-A observed across advancing age groups
• Increasing cathepsin-D levels linked to worsening metabolic profiles
• Age and biomarker patterns associated with higher insulin resistance

Keywords: Type 2 Diabetes Mellitus, Aging, Orexin-A, Cathepsin-D, Insulin Resistance

M. A. B. Khan, M. J. Hashim, J. K. King, R. D. Govender, H. Mustafa, and J. Al Kaabi, "Epidemiology of type 2 diabetes–global burden of disease and forecasted trends," J. Epidemiol. Glob. Health, vol. 10, no. 1, pp. 107-111, 2020.

H. Sun, P. Saeedi, S. Karuranga, et al., "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045," Diabetes Res. Clin. Pract., vol. 183, pp. 109119, 2022.

S. Bellary, I. Kyrou, J. E. Brown, and C. J. Bailey, "Type 2 diabetes mellitus in older adults: clinical considerations and management," Nat. Rev. Endocrinol., vol. 17, no. 9, pp. 534-548, 2021.

S. C. Schriever, D. G. Kabra, K. Pfuhlmann, et al., "Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity," J. Clin. Invest., vol. 130, no. 11, pp. 6093-6108, 2020.

R. Herman, N. A. Kravos, M. Jensterle, A. Janež, and V. Dolžan, "Metformin and insulin resistance: a review of the underlying mechanisms," Int. J. Mol. Sci., vol. 23, no. 3, pp. 1264, 2022.

X. Liu, R. Yang, W. Bai, et al., "Exploring the role of orexin B-sirtuin 1-HIF-1α in diabetes-mellitus induced vascular endothelial dysfunction," Life Sci., vol. 254, pp. 117041, 2020.

R. Van Drunen and K. Eckel-Mahan, "Circadian rhythms of the hypothalamus: from function to physiology," Clocks Sleep, vol. 3, no. 1, pp. 189-226, 2021.

J. M. Erichsen, C. B. Calva, L. P. Reagan, and J. R. Fadel, "Intranasal insulin and orexins to treat age-related cognitive decline," Physiol. Behav., vol. 234, pp. 113370, 2021.

V. Stoka, V. Turk, and B. Turk, "Lysosomal cathepsins and their regulation in aging and neurodegeneration," Ageing Res. Rev., vol. 32, pp. 22-37, 2016.

L. Ding, G. H. Goossens, Y. Oligschlaeger, et al., "Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans," Diabetologia, vol. 63, pp. 374-384, 2020.

M. Kher, S. Beri, H. S. Rehan, A. Prakash, and L. K. Gupta, "Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus," Diabetes Metab. Syndr., vol. 14, no. 6, pp. 1703-1710, 2020.

L. Liu, B. Chen, X. Zhang, L. Tan, and D. W. Wang, "Increased cathepsin D correlates with clinical parameters in newly diagnosed type 2 diabetes," Dis. Markers, vol. 2017, pp. 5286408, 2017.

H. Tsuneki, K. Honda, Y. Sekine, et al., "C-terminal peptide of preproorexin enhances brain-derived neurotrophic factor expression in rat cerebrocortical cells," Eur. J. Pharmacol., vol. 964, pp. 176306, 2024.

X. Chen, W. Yang, Y. Xue, et al., "Orexin increases the neuronal excitability of several brain areas associated with arousal maintenance," J. Neurochem., vol. 168, no. 9, pp. 2379-2390, 2024.

C. H. Sadiq, R. H. Hussein, and I. M. Maulood, "Relationship between orexin-a and insulin resistance in patients with type 2 diabetes mellitus," Iraqi J. Sci., vol. 62, no. 3, pp. 779-786, 2021.

Y. Hao, H. Yuan, P. Fang, et al., "Plasma orexin-A level associated with physical activity in obese people," Eat. Weight Disord., vol. 22, pp. 69-77, 2017.

M. Zarifkar, S. Noshad, M. Shahriari, et al., "Inverse association of peripheral orexin-A with insulin resistance in type 2 diabetes mellitus," Rev. Diabet. Stud., vol. 14, no. 2-3, pp. 301-307, 2017.

E. Yilmaz, O. Celik, N. Celik, et al., "Maternal and fetal serum orexin‐A levels in gestational diabetes mellitus," J. Obstet. Gynaecol. Res., vol. 39, no. 1, pp. 139-145, 2013.

E. Dufoo-Hurtado, A. Wall-Medrano, and R. Campos-Vega, "Naturally-derived chronobiotics in chrononutrition," Trends Food Sci. Technol., vol. 95, pp. 173-182, 2020.

D. Pocevičiūtė, B. Roth, B. Ohlsson, and M. Wennström, "Okinawa-Based Nordic Diet Decreases Plasma Levels of IAPP and IgA against IAPP Oligomers in Type 2 Diabetes Patients," Int. J. Mol. Sci., vol. 25, no. 14, pp. 7665, 2024.

L. Ding, T. J. I. De Munck, Y. Oligschlaeger, et al., "Myosteatosis in NAFLD patients correlates with plasma Cathepsin D," Biomol. Concepts, vol. 12, no. 1, pp. 27-35, 2021.

S. Reddy, A. Amutha, R. Rajalakshmi, et al., "Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients with severity of diabetic retinopathy," J. Diabetes Complications, vol. 31, no. 5, pp. 804-809, 2017.

J. Wang, J. Du, X. Ge, et al., "Circulating Ism1 reduces the risk of Type 2 diabetes but not diabetes-associated NAFLD," Front. Endocrinol., vol. 13, pp. 890332, 2022.

J. Ahmad, M. Zubair, A. Malik, M. A. Siddiqui, and S. K. Wangnoo, "Cathepsin-D, adiponectin, TNF-α, IL-6 and hsCRP plasma levels in subjects with diabetic foot," The Foot, vol. 22, no. 3, pp. 194-199, 2012.

P. Khurana, T. Yadati, S. Goyal, et al., "Inhibiting extracellular cathepsin D reduces hepatic steatosis in Sprague–Dawley rats," Biomolecules, vol. 9, no. 5, pp. 171, 2019.

L. Ding, T. Houben, Y. Oligschlaeger, et al., "Plasma cathepsin D activity rather than levels correlates with metabolic parameters of type 2 diabetes in male individuals," Front. Endocrinol., vol. 11, pp. 575070, 2020.

J. A. Rodriguez-Navarro, S. Kaushik, H. Koga, et al., "Inhibitory effect of dietary lipids on chaperone-mediated autophagy," Proc. Natl. Acad. Sci. USA, vol. 109, pp. E705-E714, 2022.

T. Min and S. C. Bain, "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes," Diabetes Ther., vol. 12, pp. 143-157, 2021.

C. N. Boyle, T. A. Lutz, and C. Le Foll, "Amylin–Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs," Mol. Metab., vol. 8, pp. 203-210, 2018.

I. Gonzalez-Mariscal, S. M. Krzysik-Walker, M. E. Doyle, et al., "Human CB1 receptor isoforms in hepatocytes and β-cells regulate metabolism," Sci. Rep., vol. 6, no. 1, pp. 33302, 2016.